KMDA
KAMADA LTDPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 11 ▲ Kamada Ltd. reported strong 2025 full-year results with revenue of $…
- Jul 20 ▲ Kamada announced a three-year agreement to supply normal source plas…
- Aug 12 ▲ Kamada reported record-high Q2 and H1 2026 results with double-digit…
- Aug 12 Leadership: Kamada Announces Planned Transition of Chief Financial Off…
- Aug 17 ▲ Kamada Ltd. reported record-high revenue and profitability for the f…
- Sep 3 Dividend: Kamada Updates on Withholding Tax Procedures on Previously…
- Sep 7 to Sep 14 ▼ 4 days of insider sells: $1.7M by 1 insider, avg $8.25
- Sep 17 ▲ Kamada confirms sufficient KedRAB supply and manufacturing capacity…
- Sep 30 ▼ Short interest jumps 30.3% to 209.5K
- Oct 6 ▲ Kamada announced the commercial launch of two new biosimilars in Isr…
- Nov 9 ▲ Kamada reported record Q3 2026 revenue of $52.0M (up 11% YoY) and ne…
- Nov 9 ▲ Kamada reported Q3 2026 revenue of $52.0M (+11% YoY) and EPS of $0.1…
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider sold $1.7M.
- InstitutionsBULLISH
Q3 2026: 12 added (0 new), 2 trimmed or exited.
- Short sellersCOVERING
Short interest −16.1% to 165.8K shares. 2.6 days to cover, ≈0.3% of shares.
- TrendRANGE
1% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MARSHALL WACE, LLP | DOUBLED | $1.6M |
| JANE STREET GROUP, LLC | DOUBLED | $870.1K |
| Quadrature Capital Ltd | DOUBLED | $665.4K |
| UBS Group AG | DOUBLED | $595.8K |
| STIFEL FINANCIAL CORP | ADD | $579.7K |
| BARCLAYS PLC | DOUBLED | $371.2K |
| MORGAN STANLEY | ADD | $136.2K |
| JPMORGAN CHASE & CO | TRIM | $98.7K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Dec 2025Price is below the lowest target. Median implies +73%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Dec 9, 2025 | HC Wainwright & Co. MAINTAIN | Buy |
| May 15, 2025 | Benchmark REITERATE | Buy |
| Mar 21, 2025 | Benchmark INITIATE | Buy |
| Mar 6, 2025 | HC Wainwright & Co. REITERATE | Buy |
| Jan 10, 2025 | HC Wainwright & Co. REITERATE | Buy |
| Nov 14, 2024 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Tsur David Director Sep 14, 2026 | SELL | $186.7K |
Livneh Nir VP, General Counsel Sep 14, 2026 | EXERCISE | $53.7K |
Livneh Nir VP, General Counsel Sep 14, 2026 | TAX W/H | $28.9K |
Brenner Yael VP Quality Sep 14, 2026 | EXERCISE | $29.6K |
Brenner Yael VP Quality Sep 14, 2026 | TAX W/H | $11.5K |
Brenner Yael VP Quality Sep 14, 2026 | EXERCISE | $38.5K |
Brenner Yael VP Quality Sep 14, 2026 | TAX W/H | $14.9K |
Brenner Yael VP Quality Sep 14, 2026 | EXERCISE | $32.4K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
21 filings · 4 press releases · 9 bullish · 1 bearish · 11 neutral- BULLISH 6-KNov 9, 2026
Kamada reported record Q3 2026 revenue of $52.0M (up 11% YoY) and net income of $8.0M…
The raised guidance and projection of double-digit growth in 2027 signal sustained momentum. Watch for the January 2027 detailed guidance and any M&A announcements that could accelerate growth…
- BULLISH PRESS-RELEASENov 9, 2026
Kamada reported Q3 2026 revenue of $52.0M (+11% YoY) and EPS of $0.14, beating the $0.13…
The raised guidance and strong cash generation support continued organic growth. Watch for the January 2027 detailed guidance and any M&A announcements that could further accelerate growth.
- NEUTRAL 6-KNov 2, 2026
Kamada Ltd. filed a Form 6-K announcing that it will release Q3 and nine-month 2026 financial…
Monitor the November 9 earnings release for Q3 2026 revenue and EPS against consensus of $157.4M and $0.13 per ADS, respectively. The prior quarter (Q2 2026) showed a beat versus consensus.
- NEUTRAL 6-KOct 6, 2026
Kamada announced the commercial launch of two new biosimilar products in Israel…
Monitor upcoming quarterly filings for actual biosimilar sales traction and any updates on the pipeline of additional products expected in 2027. The long-term revenue projections ($20-25M by 2030)…
All KMDA filing & press-release reports (25)
- 6-K reportNov 9, 2026
- PRESS-RELEASE reportNov 9, 2026
- 6-K reportNov 2, 2026
- 6-K reportOct 6, 2026
- PRESS-RELEASE reportOct 6, 2026
- 6-K reportOct 5, 2026
- 6-K reportSep 17, 2026
- EFFECT reportSep 16, 2026
- 6-K reportSep 10, 2026
- PRESS-RELEASE reportSep 3, 2026
- 6-K reportSep 3, 2026
- 6-K, PRESS-RELEASE reportAug 17, 2026
- 6-K reportAug 12, 2026
- 6-K reportAug 5, 2026
- 6-K reportAug 5, 2026
- 6-K reportJul 20, 2026
- 6-K reportJul 13, 2026
- 6-K reportJun 18, 2026
- 6-K reportJun 1, 2026
- PRESS-RELEASE reportMay 13, 2026
- 6-K reportMar 31, 2026
- 6-K reportMar 26, 2026
- PRESS-RELEASE reportMar 26, 2026
- PRESS-RELEASE reportMar 11, 2026
- PRESS-RELEASE reportMar 11, 2026